REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Atypical Chemokine Receptor 4 Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Serine338/Threonine342 phosphorylation of the Atypical Chemokine Receptor  4
pS338/pT342-ACKR4 (phospho-Atypical Chemokine...
Serine338/Threonine342 (S338/T342) is major phosphorylation site of the Atypical Chemokine Receptor 4 (ACKR4). The pS338/pT342-ACKR4 antibody detects phosphorylation in response to agonists. S338/ST42 phosphorylation is likely to be...
$ 350.00
NEW
Validation of Atypical Chemokine Receptor 4 in transfected HEK293 cells
ACKR4 (non-phospho), Atypical Chemokine...
The ACKR4 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Atypical Chemokine Receptor 4. It can be used to detect total ACKR4 receptors in Western blots independent of phosphorylation. The...
$ 350.00

ACKR4

The atypical chemokine receptor 4 (ACKR4) acts as chemokine scavenger (also known as chemokine decoy receptor). ACKR4 can sequester a broad range of chemokines including CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25. Chemokine-binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization. ACKR4 plays an important role in controlling the migration of immune and cancer cells that express chemokine receptors CCR7 and CCR9, by reducing the availability of CCL19, CCL21, and CCL25 through internalization. ACKR4 negatively regulates CXCR3-induced chemotaxis. ACKR4 also regulates T-cell development in the thymus. ACKR4 receptor function is regulated by phosphorylation of carboxyl-terminal serine338/threonine342 (pS338/pT342-ACKR4). This nomenclature refers to the human ACKR4 receptor. This phosphorylation motif is highly conserved across species and is identical in mice and humans. For more information on ACKR4 pharmacology please refer to the IUPHAR database. For further reading refer to:

 Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

The atypical chemokine receptor 4 (ACKR4) acts as chemokine scavenger (also known as chemokine decoy receptor). ACKR4 can sequester a broad range of chemokines including CCL2, CCL8, CCL13,... read more »
Close window
Atypical Chemokine Receptor 4 Antibodies

ACKR4

The atypical chemokine receptor 4 (ACKR4) acts as chemokine scavenger (also known as chemokine decoy receptor). ACKR4 can sequester a broad range of chemokines including CCL2, CCL8, CCL13, CCL19, CCL21 and CCL25. Chemokine-binding does not activate G-protein-mediated signal transduction but instead induces beta-arrestin recruitment, leading to ligand internalization. ACKR4 plays an important role in controlling the migration of immune and cancer cells that express chemokine receptors CCR7 and CCR9, by reducing the availability of CCL19, CCL21, and CCL25 through internalization. ACKR4 negatively regulates CXCR3-induced chemotaxis. ACKR4 also regulates T-cell development in the thymus. ACKR4 receptor function is regulated by phosphorylation of carboxyl-terminal serine338/threonine342 (pS338/pT342-ACKR4). This nomenclature refers to the human ACKR4 receptor. This phosphorylation motif is highly conserved across species and is identical in mice and humans. For more information on ACKR4 pharmacology please refer to the IUPHAR database. For further reading refer to:

 Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, Mantovani A, Matsushima K, Murphy PM, Nibbs R, Nomiyama H, Power CA, Proudfoot AE, Rosenkilde MM, Rot A, Sozzani S, Thelen M, Yoshie O, Zlotnik A. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2013 Nov 11;66(1):1-79. doi: 10.1124/pr.113.007724. Print 2014. Review. Erratum in: Pharmacol Rev. 2014 Apr;66(2):467. PubMed PMID: 24218476; PubMed Central PMCID: PMC3880466.

Recently viewed